21 patients with chronic neuropathic pain received increasing doses of a synthetic cannabinoid (CT-3) or placebo for 1 week in a random order. The primary outcome was pain reduction, measured by the Visual Analogue Scale (VAS) and Verbal Rating Scale (VRS). Psychoactive effects were also assessed by the Trail-Making Test (TMT) and Addiction Research Center Inventory-Marijuana (ARCI-M), and adverse events (AEs) were recorded. Results indicate that CT-3 significantly reduced pain compared to placebo, but was also associated with an increased rate of non-major adverse events. The treatments were comparable with regards to ARCI-M and TMT scores, as well as vital signs, weight, and temperature.